Article: QIAGEN Extends Distribution Agreement With Abbott for QIAGEN's RealArt(TM) Molecular Diagnostic Tests.

VENLO, The Netherlands, June 22 /PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins today announced that Abbott and QIAGEN have extended their existing distribution agreement. Under the terms of the agreement, Abbott received distribution rights to a number of real-time PCR diagnostic tests for use on Applied Biosystems detection instruments. The PCR assays were developed by artus GmbH, a company QIAGEN recently acquired.

Under the extended agreement Abbott has non-exclusive ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!